Sustainability Report

The report describes BioArctic's focus on patient access, noting that Leqembi was approved in more than 50 markets, and reports that 66 percent of total costs were reinvested in research. It also highlights workforce growth to 131 employees and an average 2025 eNPS of 79. Environmental goals include a 65 percent reduction of CO2 in the value chain by 2035 and net zero by 2050.